Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARMEN CD 307 maintenance study of ontamalimab in moderate to severe Crohn's disease
NL-OMON50298Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ontamalimab in Crohn's disease (3 arms), sponsored by Takeda. Primary endpoints: Clinical remission based on 2-item patient-reported outcome and Enhanced endoscopic response. Started Feb 2020; status: completed.
02
Drugs
ontamalimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON50298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50298.